<p>随着 2025 年接近尾声，主要的美国股票指数表现不一，近期的下跌掩盖了由科技公司推动的显著年度收益。在这种背景下，虽然 “便士股票” 这一术语已显得过时，但它们仍然具有相关性，因为它们通常代表较小或新兴的公司，能够提供独特的投资机会。通过关注那些财务状况良好且具有增长潜力的公司，投资者可能会在这些鲜为人知的股票中发现有前景的投资机会。</p>
<h3>美国十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.49</td>
<td>$574.34M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.89</td>
<td>$679.93M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8343</td>
<td>$142.68M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.29</td>
<td>$553.59M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.14</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.24</td>
<td>$556.91M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Nephros (NEPH)</td>
<td>$4.72</td>
<td>$50.16M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.98</td>
<td>$7.12M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.97</td>
<td>$89.94M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国便士股票筛选器的 341 只股票的完整列表。</p>
<p>让我们从我们的专业筛选器中发现一些宝藏。</p>
<h2>Anavex Life Sciences (AVXL)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Anavex Life Sciences Corp. 是一家生物制药公司，市值约为 3.3952 亿美元。</p>
<p><strong>运营：</strong> Anavex Life Sciences Corp. 目前没有报告任何收入细分。</p>
<p><strong>市值：</strong> $339.52M</p>
<p>Anavex Life Sciences 的市值为 3.3952 亿美元，尚未产生收入，专注于开发阿尔茨海默病和精神分裂症的治疗方案。尽管尚未盈利，该公司拥有超过两年的稳定现金流，并且没有债务负担。最近的发展包括在欧盟面临关于阿尔茨海默病治疗的 blarcamesine 的监管挑战，此前欧洲药品管理局的药品委员会发表了负面意见。Anavex 正在寻求重新审查，同时也与美国 FDA 就临床试验结果进行沟通。管理团队的平均任期为 3.9 年，表明在应对这些复杂过程方面具有经验。</p>
<ul>
<li>通过我们的全面资产负债表健康报告，深入了解 Anavex Life Sciences 的复杂性。</li>
<li>在这里了解 Anavex Life Sciences 的未来增长轨迹。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5eab7da-d0bc-4781-b806-400cacdddf7d/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5eab7da-d0bc-4781-b806-400cacdddf7d/chart/financial-position-analysis"/></p>
<p>截至 2025 年 12 月的 AVXL 财务状况分析</p>
<h2>Caesarstone (CSTE)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Caesarstone Ltd. 设计、开发、制造和销售工程石材和瓷器产品，覆盖多个全球市场，市值为 6566 万美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自其建筑产品部门，总计 4.0066 亿美元。</p>
<p><strong>市值：</strong> $65.66M</p>
<p>Caesarstone Ltd. 的市值为 6566 万美元，面临财务挑战，最近的财报显示 2025 年第三季度净亏损为 1810 万美元，较去年有所增加。尽管出现这些亏损，公司仍然保持现金多于总债务，并且短期资产超过负债，显示出一定的财务稳定性。最近的战略重组努力包括关闭以色列的一家制造设施，以提高竞争力和盈利能力。管理层变动带来了经验丰富的领导，Yaron Arzi 被任命为董事会成员，可能有助于应对持续的运营调整和市场需求。</p>
<ul>
<li>在此财务健康报告中解锁我们对 Caesarstone 股票的全面洞察。</li>
<li>在我们的增长报告中探索 Caesarstone 的分析师预测。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/240901f4-ee73-418f-9d8d-4ecf64ca43f7/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/240901f4-ee73-418f-9d8d-4ecf64ca43f7/chart/financial-position-analysis"/></p>
<p>截至 2025 年 12 月的 CSTE 财务状况分析</p>
<h2>Realbotix (XBOT.F)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Realbotix Corp. 的市值为 6703 万美元，开发可定制的人形机器人，并在加拿大集成人工智能。</p>
<p><strong>运营：</strong> 公司的收入完全来自加拿大，总计 270 万美元。</p>
<p><strong>市值：</strong> $67.03M</p>
<p>Realbotix Corp. 的市值为 6703 万美元，在便士股票市场中面临机遇与挑战。该公司最近通过私人配售筹集了 700 万加元，以增强其财务流动性，最初预计可持续五个月。尽管尚未盈利，Realbotix 的短期资产超过负债，且现金多于债务，提供了一定的财务缓冲。Scott Meyers 被任命为首席财务官，旨在加强公司财务战略，以应对全球扩张的努力。即将在 2026 年 CES 展会上展示的 AI 驱动人形机器人，可能会提升市场知名度和投资者兴趣。</p>
<ul>
<li>点击探索我们对 Realbotix 财务健康报告的详细分析。</li>
<li>通过我们的详细增长报告评估 Realbotix 的未来收益预期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8ab15b3e-1939-49d0-a96c-08987aa5df64/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8ab15b3e-1939-49d0-a96c-08987aa5df64/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 12 月的 XBOT.F 债务与股本历史及分析</p>
<h2>接下来该如何做？</h2>
<ul>
<li>点击此链接访问 341 只美国便士股票的完整列表。</li>
<li>寻找替代机会？这 16 家公司在 COVID 后生存并蓬勃发展，具备应对特朗普关税的必要条件。在您的投资组合感受到贸易战的压力之前，了解原因。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章性质一般。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>国防与灾难的移动基础设施</p>
<p>下一波机器人技术不是人形机器人，而是能够在 30 分钟内提供 5G、ISR 和雷达的完全自主塔。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

AVXL

叮咚买菜

水滴

<p>随着 2025 年的临近，美国股指表现不一，便宜股因其潜力而受到关注。值得注意的股票包括：叮咚买菜（DDL），市值为 5.7434 亿美元；水滴（WDH），市值为 6.7993 亿美元；以及专注于阿尔茨海默病治疗的 Anavex Life Sciences（AVXL），市值为 3.3952 亿美元。Caesarstone（CSTE）面临挑战，市值为 6566 万美元，并且最近出现了净亏损，而 Realbotix（XBOT.F）市值为 6703 万美元，正在人工智能机器人领域扩展。投资者被鼓励在市场波动中探索这些机会</p>

<p>As 2025 draws to a close, major U.S. stock indexes have experienced a mixed performance, with recent declines overshadowing a year of substantial gains driven by technology firms. In this context, penny stocks—though an outdated term—remain relevant as they often represent smaller or emerging companies that can offer unique investment opportunities. By focusing on those with strong financials and growth potential, investors may uncover promising prospects among these lesser-known stocks.</p>
<div class="lb-trans"><p>随着 2025 年接近尾声，主要的美国股票指数表现不一，近期的下跌掩盖了由科技公司推动的显著年度收益。在这种背景下，虽然 “便士股票” 这一术语已显得过时，但它们仍然具有相关性，因为它们通常代表较小或新兴的公司，能够提供独特的投资机会。通过关注那些财务状况良好且具有增长潜力的公司，投资者可能会在这些鲜为人知的股票中发现有前景的投资机会。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.49</td>
<td>$574.34M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.89</td>
<td>$679.93M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8343</td>
<td>$142.68M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.29</td>
<td>$553.59M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.14</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.24</td>
<td>$556.91M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Nephros (NEPH)</td>
<td>$4.72</td>
<td>$50.16M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.98</td>
<td>$7.12M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.97</td>
<td>$89.94M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.49</td>
<td>$574.34M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.89</td>
<td>$679.93M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8343</td>
<td>$142.68M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.29</td>
<td>$553.59M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.14</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.24</td>
<td>$556.91M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Nephros (NEPH)</td>
<td>$4.72</td>
<td>$50.16M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.98</td>
<td>$7.12M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.97</td>
<td>$89.94M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 341 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国便士股票筛选器的 341 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>让我们从我们的专业筛选器中发现一些宝藏。</p>
</div><h2>Anavex Life Sciences (AVXL)</h2>
<div class="lb-trans"><h2>Anavex Life Sciences (AVXL)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Anavex Life Sciences Corp. is a biopharmaceutical company with a market cap of approximately $339.52 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Anavex Life Sciences Corp. 是一家生物制药公司，市值约为 3.3952 亿美元。</p>
</div><p><strong>Operations:</strong> Anavex Life Sciences Corp. currently does not report any revenue segments.</p>
<div class="lb-trans"><p><strong>运营：</strong> Anavex Life Sciences Corp. 目前没有报告任何收入细分。</p>
</div><p><strong>Market Cap:</strong> $339.52M</p>
<div class="lb-trans"><p><strong>市值：</strong> $339.52M</p>
</div><p>Anavex Life Sciences, with a market cap of US$339.52 million, is pre-revenue and focused on developing treatments for Alzheimer's disease and schizophrenia. Despite being unprofitable, the company has a stable cash runway exceeding two years and no debt liabilities. Recent developments include regulatory challenges in the EU concerning blarcamesine for Alzheimer's treatment, following a negative opinion from the European Medicines Agency's Committee for Medicinal Products. Anavex is seeking re-examination while also engaging with U.S. FDA regarding clinical trial results. The management team has an average tenure of 3.9 years, indicating experience in navigating these complex processes.</p>
<div class="lb-trans"><p>Anavex Life Sciences 的市值为 3.3952 亿美元，尚未产生收入，专注于开发阿尔茨海默病和精神分裂症的治疗方案。尽管尚未盈利，该公司拥有超过两年的稳定现金流，并且没有债务负担。最近的发展包括在欧盟面临关于阿尔茨海默病治疗的 blarcamesine 的监管挑战，此前欧洲药品管理局的药品委员会发表了负面意见。Anavex 正在寻求重新审查，同时也与美国 FDA 就临床试验结果进行沟通。管理团队的平均任期为 3.9 年，表明在应对这些复杂过程方面具有经验。</p>
</div><ul>
<li>Navigate through the intricacies of Anavex Life Sciences with our comprehensive balance sheet health report here.</li>
<li>Learn about Anavex Life Sciences' future growth trajectory here.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的全面资产负债表健康报告，深入了解 Anavex Life Sciences 的复杂性。</li>
<li>在这里了解 Anavex Life Sciences 的未来增长轨迹。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5eab7da-d0bc-4781-b806-400cacdddf7d/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/d5eab7da-d0bc-4781-b806-400cacdddf7d/chart/financial-position-analysis"/></p>
<p>AVXL Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 AVXL 财务状况分析</p>
</div><h2>Caesarstone (CSTE)</h2>
<div class="lb-trans"><h2>Caesarstone (CSTE)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Caesarstone Ltd. designs, develops, manufactures, and sells engineered stone and porcelain products across various global markets under its own brands, with a market cap of $65.66 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Caesarstone Ltd. 设计、开发、制造和销售工程石材和瓷器产品，覆盖多个全球市场，市值为 6566 万美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Building Products segment, totaling $400.66 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其建筑产品部门，总计 4.0066 亿美元。</p>
</div><p><strong>Market Cap:</strong> $65.66M</p>
<div class="lb-trans"><p><strong>市值：</strong> $65.66M</p>
</div><p>Caesarstone Ltd., with a market cap of US$65.66 million, is facing financial challenges as evidenced by its recent earnings report showing a net loss of US$18.1 million for Q3 2025, up from the previous year. Despite these losses, the company maintains more cash than total debt and has short-term assets exceeding liabilities, indicating some financial stability. Recent strategic restructuring efforts include closing a manufacturing facility in Israel to improve competitiveness and profitability. Management changes bring experienced leadership with Yaron Arzi's appointment to the board, potentially aiding in navigating ongoing operational adjustments and market demands.</p>
<div class="lb-trans"><p>Caesarstone Ltd. 的市值为 6566 万美元，面临财务挑战，最近的财报显示 2025 年第三季度净亏损为 1810 万美元，较去年有所增加。尽管出现这些亏损，公司仍然保持现金多于总债务，并且短期资产超过负债，显示出一定的财务稳定性。最近的战略重组努力包括关闭以色列的一家制造设施，以提高竞争力和盈利能力。管理层变动带来了经验丰富的领导，Yaron Arzi 被任命为董事会成员，可能有助于应对持续的运营调整和市场需求。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Caesarstone stock in this financial health report.</li>
<li>Explore Caesarstone's analyst forecasts in our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在此财务健康报告中解锁我们对 Caesarstone 股票的全面洞察。</li>
<li>在我们的增长报告中探索 Caesarstone 的分析师预测。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/240901f4-ee73-418f-9d8d-4ecf64ca43f7/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/240901f4-ee73-418f-9d8d-4ecf64ca43f7/chart/financial-position-analysis"/></p>
<p>CSTE Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 CSTE 财务状况分析</p>
</div><h2>Realbotix (XBOT.F)</h2>
<div class="lb-trans"><h2>Realbotix (XBOT.F)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Realbotix Corp., with a market cap of $67.03 million, develops customizable human-like robots with artificial intelligence integration in Canada.</p>
<div class="lb-trans"><p><strong>概述：</strong> Realbotix Corp. 的市值为 6703 万美元，开发可定制的人形机器人，并在加拿大集成人工智能。</p>
</div><p><strong>Operations:</strong> The company's revenue segment is derived entirely from Canada, totaling $2.70 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入完全来自加拿大，总计 270 万美元。</p>
</div><p><strong>Market Cap:</strong> $67.03M</p>
<div class="lb-trans"><p><strong>市值：</strong> $67.03M</p>
</div><p>Realbotix Corp., with a market cap of $67.03 million, is navigating the penny stock landscape with both opportunities and challenges. The company has recently raised CAD 7 million through private placements to bolster its financial runway, which was initially forecasted to last five months. Despite being unprofitable, Realbotix's short-term assets exceed liabilities and it holds more cash than debt, providing some financial cushion. The appointment of Scott Meyers as CFO aims to strengthen corporate finance strategies amid global expansion efforts. Upcoming showcases at CES 2026 highlight advancements in AI-powered humanoid robots, potentially enhancing market visibility and investor interest.</p>
<div class="lb-trans"><p>Realbotix Corp. 的市值为 6703 万美元，在便士股票市场中面临机遇与挑战。该公司最近通过私人配售筹集了 700 万加元，以增强其财务流动性，最初预计可持续五个月。尽管尚未盈利，Realbotix 的短期资产超过负债，且现金多于债务，提供了一定的财务缓冲。Scott Meyers 被任命为首席财务官，旨在加强公司财务战略，以应对全球扩张的努力。即将在 2026 年 CES 展会上展示的 AI 驱动人形机器人，可能会提升市场知名度和投资者兴趣。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Realbotix's financial health report.</li>
<li>Assess Realbotix's future earnings estimates with our detailed growth reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们对 Realbotix 财务健康报告的详细分析。</li>
<li>通过我们的详细增长报告评估 Realbotix 的未来收益预期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8ab15b3e-1939-49d0-a96c-08987aa5df64/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/8ab15b3e-1939-49d0-a96c-08987aa5df64/chart/debt-equity-history-analysis"/></p>
<p>XBOT.F Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 XBOT.F 债务与股本历史及分析</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下来该如何做？</h2>
</div><ul>
<li>Access the full spectrum of 341 US Penny Stocks by clicking on this link.</li>
<li>Looking For Alternative Opportunities? These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击此链接访问 341 只美国便士股票的完整列表。</li>
<li>寻找替代机会？这 16 家公司在 COVID 后生存并蓬勃发展，具备应对特朗普关税的必要条件。在您的投资组合感受到贸易战的压力之前，了解原因。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章性质一般。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>国防与灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是人形机器人，而是能够在 30 分钟内提供 5G、ISR 和雷达的完全自主塔。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

分析三只市值超过 6000 万美元的潜力便士股